Cargando…

Ultrasound-Guided Injection of High Molecular Weight Hyaluronic Acid versus Corticosteroid in Management of Plantar Fasciitis: A 24-Week Randomized Clinical Trial

BACKGROUND AND AIMS: Plantar fasciitis (PF) is the leading cause of heel pain in adults. This study was designed to evaluate the effect of hyaluronic acid (HA) injection in reducing the symptoms of PF, compared with corticosteroid (CS) injection as a conventional treatment. METHODS: In this triple-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Raeissadat, Seyed Ahmad, Nouri, Farshad, Darvish, Mahtab, Esmaily, Hadi, Ghazihosseini, Parsa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969680/
https://www.ncbi.nlm.nih.gov/pubmed/32021400
http://dx.doi.org/10.2147/JPR.S217419
_version_ 1783489359549300736
author Raeissadat, Seyed Ahmad
Nouri, Farshad
Darvish, Mahtab
Esmaily, Hadi
Ghazihosseini, Parsa
author_facet Raeissadat, Seyed Ahmad
Nouri, Farshad
Darvish, Mahtab
Esmaily, Hadi
Ghazihosseini, Parsa
author_sort Raeissadat, Seyed Ahmad
collection PubMed
description BACKGROUND AND AIMS: Plantar fasciitis (PF) is the leading cause of heel pain in adults. This study was designed to evaluate the effect of hyaluronic acid (HA) injection in reducing the symptoms of PF, compared with corticosteroid (CS) injection as a conventional treatment. METHODS: In this triple-blind, randomized, clinical trial, 75 patients who had the symptoms of PF for at least 3 months were randomly divided into two groups of 38 and 37 individuals. Then, each patient received either a single injection of high molecular weight (>2000 kDa) HA (1 mL HA 20 mg + 1 mL lidocaine 2%) or CS (1 mL methylprednisolone 40 mg + 1 mL lidocaine 2%) under the ultrasonography (US) guidance. Visual analog scale (VAS), foot ankle ability index (FAAI), pressure pain threshold (PPT), functional foot index (FFI), and plantar fascia thickness (PFT) were measured using US at baseline, 6 weeks and 24 weeks after the injection. Eventually, at the end of the treatment period, the patients’ satisfaction was measured. Intention to treat analysis was used to assess the results. RESULTS: After 24 weeks of follow-up, results from 60 subjects were fully obtained; however, results of 73 patients included into intention to treat analysis in the sixth-week follow-up. In both groups, VAS, PFT and FFI decreased, while FAAI and PPT increased significantly (P <0.001). At the baseline and at the 24th-week, no significant difference between the two groups was observed in any of the variables. However, a comparison between the baseline and the sixth-week results shows a prominent decrease in PPT and PFT in the CS group compared to the HA group (P = 0.004 and P = 0.011). Finally, there were no statistical differences between the two groups in treatment satisfaction (P = 0.618). CONCLUSION: Both CS and HA were effective modalities for PF and can improve pain and function with no superiority in 24th-week follow-ups, although CS seems to have a faster trend of improvement in the short term.
format Online
Article
Text
id pubmed-6969680
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69696802020-02-04 Ultrasound-Guided Injection of High Molecular Weight Hyaluronic Acid versus Corticosteroid in Management of Plantar Fasciitis: A 24-Week Randomized Clinical Trial Raeissadat, Seyed Ahmad Nouri, Farshad Darvish, Mahtab Esmaily, Hadi Ghazihosseini, Parsa J Pain Res Clinical Trial Report BACKGROUND AND AIMS: Plantar fasciitis (PF) is the leading cause of heel pain in adults. This study was designed to evaluate the effect of hyaluronic acid (HA) injection in reducing the symptoms of PF, compared with corticosteroid (CS) injection as a conventional treatment. METHODS: In this triple-blind, randomized, clinical trial, 75 patients who had the symptoms of PF for at least 3 months were randomly divided into two groups of 38 and 37 individuals. Then, each patient received either a single injection of high molecular weight (>2000 kDa) HA (1 mL HA 20 mg + 1 mL lidocaine 2%) or CS (1 mL methylprednisolone 40 mg + 1 mL lidocaine 2%) under the ultrasonography (US) guidance. Visual analog scale (VAS), foot ankle ability index (FAAI), pressure pain threshold (PPT), functional foot index (FFI), and plantar fascia thickness (PFT) were measured using US at baseline, 6 weeks and 24 weeks after the injection. Eventually, at the end of the treatment period, the patients’ satisfaction was measured. Intention to treat analysis was used to assess the results. RESULTS: After 24 weeks of follow-up, results from 60 subjects were fully obtained; however, results of 73 patients included into intention to treat analysis in the sixth-week follow-up. In both groups, VAS, PFT and FFI decreased, while FAAI and PPT increased significantly (P <0.001). At the baseline and at the 24th-week, no significant difference between the two groups was observed in any of the variables. However, a comparison between the baseline and the sixth-week results shows a prominent decrease in PPT and PFT in the CS group compared to the HA group (P = 0.004 and P = 0.011). Finally, there were no statistical differences between the two groups in treatment satisfaction (P = 0.618). CONCLUSION: Both CS and HA were effective modalities for PF and can improve pain and function with no superiority in 24th-week follow-ups, although CS seems to have a faster trend of improvement in the short term. Dove 2020-01-14 /pmc/articles/PMC6969680/ /pubmed/32021400 http://dx.doi.org/10.2147/JPR.S217419 Text en © 2020 Raeissadat et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Clinical Trial Report
Raeissadat, Seyed Ahmad
Nouri, Farshad
Darvish, Mahtab
Esmaily, Hadi
Ghazihosseini, Parsa
Ultrasound-Guided Injection of High Molecular Weight Hyaluronic Acid versus Corticosteroid in Management of Plantar Fasciitis: A 24-Week Randomized Clinical Trial
title Ultrasound-Guided Injection of High Molecular Weight Hyaluronic Acid versus Corticosteroid in Management of Plantar Fasciitis: A 24-Week Randomized Clinical Trial
title_full Ultrasound-Guided Injection of High Molecular Weight Hyaluronic Acid versus Corticosteroid in Management of Plantar Fasciitis: A 24-Week Randomized Clinical Trial
title_fullStr Ultrasound-Guided Injection of High Molecular Weight Hyaluronic Acid versus Corticosteroid in Management of Plantar Fasciitis: A 24-Week Randomized Clinical Trial
title_full_unstemmed Ultrasound-Guided Injection of High Molecular Weight Hyaluronic Acid versus Corticosteroid in Management of Plantar Fasciitis: A 24-Week Randomized Clinical Trial
title_short Ultrasound-Guided Injection of High Molecular Weight Hyaluronic Acid versus Corticosteroid in Management of Plantar Fasciitis: A 24-Week Randomized Clinical Trial
title_sort ultrasound-guided injection of high molecular weight hyaluronic acid versus corticosteroid in management of plantar fasciitis: a 24-week randomized clinical trial
topic Clinical Trial Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969680/
https://www.ncbi.nlm.nih.gov/pubmed/32021400
http://dx.doi.org/10.2147/JPR.S217419
work_keys_str_mv AT raeissadatseyedahmad ultrasoundguidedinjectionofhighmolecularweighthyaluronicacidversuscorticosteroidinmanagementofplantarfasciitisa24weekrandomizedclinicaltrial
AT nourifarshad ultrasoundguidedinjectionofhighmolecularweighthyaluronicacidversuscorticosteroidinmanagementofplantarfasciitisa24weekrandomizedclinicaltrial
AT darvishmahtab ultrasoundguidedinjectionofhighmolecularweighthyaluronicacidversuscorticosteroidinmanagementofplantarfasciitisa24weekrandomizedclinicaltrial
AT esmailyhadi ultrasoundguidedinjectionofhighmolecularweighthyaluronicacidversuscorticosteroidinmanagementofplantarfasciitisa24weekrandomizedclinicaltrial
AT ghazihosseiniparsa ultrasoundguidedinjectionofhighmolecularweighthyaluronicacidversuscorticosteroidinmanagementofplantarfasciitisa24weekrandomizedclinicaltrial